This trial is evaluating whether Single Photon Emission Computed Tomography will improve 2 primary outcomes and 4 secondary outcomes in patients with Stage III Lung Cancer AJCC v8. Measurement will happen over the course of Within 12-month of completion of CRT].
This trial requires 100 total participants across 2 different treatment groups
This trial involves 2 different treatments. Single Photon Emission Computed Tomography is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
The cause of stage iii [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)s is not well understood. Although cancer is caused in part by environmental exposures, genetic factors have been shown to occur as the first step in cancer genesis. A few well established environmental factors are suggested, but further work is required.
Stage iii cancer of the lung is a group of cancer that tends to invade the lung tissues but that usually does not spread to other areas. Symptoms can include cough, dyspnea (shortness of breath) on exertion, chest pain and/or weight loss as the disease worsens. Patients with this type of lung (or in rare cases, other types of cancers) will often have stage iii lung cancer detected earlier in time by their signs and symptoms. Early detection through screening lowers the probability of having a late-stage (iv or v stages) cancer.
stage iii is the most prevalent stage of [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) in our study group with a maximum depth of tumor in stage iii of 14 cm or greater. In a review of the published series, the median survival for stage iii cancer is only 12 months with the 5-year survival rate of 29%. Stage iii can be diagnosed only after surgery once a pathologically proven diagnosis of lung cancer by an experienced pathologist is obtained.
Stage iii lung cancer is rare in the United States. It is more prevalent in certain population groups. Most notably, non-Hispanic blacks and Hispanic women have increased rates. Stage iii lung cancer should remain as one of the top categories in staging and reporting of lung cancer.
Tumor cell-to-stromal ratio, %CD90, p53 and p16 expression were found to be independent prognostic factors in stage iii lung cancer. Patients with tumor cell-to-stromal ratio>0.1 and %CD90>20% and p53 < 15% showed improved overall survival. Lymph node metastases and age were found to be independent prognostic factors, and in vitro chemotherapy, cisplatin, etoposide, and cisplatin had a positive effect on overall survival.
Patients with stage iii lung cancer can be treated effectively with an approved medication (pemetrexed) in combination with platinum analogs. This regimen was found to be well tolerated, with excellent responses in approximately 25% of patients.
There are, as of March 2013, still no effective treatments for metastatic [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer), though surgery for stage iii tumors still is a standard treatment in America. Current strategies are only temporarily effective and in some patients have a low survival rate. The problem with lung cancer in general is that only 5% people die of this form of cancer. In some cases, lung cancer is inoperable and has a very poor prognosis. For individuals with this form of lung cancer, there are several promising treatment options including [Targeted therapies.(http://www.nfl.com/nfl/news/2011/10/01/lung-cancer_pilot_program_is_launched_in_texas.
Stage iii tumors can spread early but are most likely to spread within the first 3 years. However, stage iii cancer will continue to spread to other parts of the body for up to 15 years. Stage iii lung cancer is treated with surgery, radiation therapy, and often multiple rounds of chemotherapy that can cause a number of serious side effects.
This article presents data from four Phase II clinical trials. In a recent study, findings provide the background and rationale necessary for the design of the next Phase III trial in the treatment of MCL in patients with a biologic or symptomatic response after two preceding chemotherapy-based treatment regimens.
The overall incidence of serious adverse events associated to the collection of any biospecimen is minimal. We identified the collection of blood as a potential biospecimen with a higher frequency of serious adverse events.
Patients participating in trials often require collection of biospecimens. The addition of such collection to conventional therapy adds little extra value beyond the already offered by a trial.